Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jordanian Drug Maker Buys Baxter Injectable Business, Becomes Second Largest In U.S.

This article was originally published in PharmAsia News

Executive Summary

Fast-growing Jordanian drug maker Hikma will acquire Baxter Healthcare's U.S. generic injectables business for $112 million. The acquisition doubles Hikma's injectables business and bolsters the company to the No. 2 position in the U.S. market with a projected market share of more than 15 percent. It also solidifies Hikma's leading position in the Middle East and North African (MENA) market, one of the rapidly growing "pharmerging" markets in the world

You may also be interested in...



Hikma Looks To Be Partner Of Choice In MENA Region Via Acquisition Of Promopharm

Jordanian drug maker Hikma Pharmaceuticals PLC acquired 63.9% of Moroccan branded generics firm Promopharm SA Oct. 3 in a cash deal worth $111.2 million. The acquisition gives Hikma access to the fourth largest pharmaceutical market in the Middle East and North Africa, additional manufacturing capacity and capability, and a perhaps stronger claim to its goal of being a partner of choice for multinationals across the MENA region

Hikma Looks To Be Partner Of Choice In MENA Region Via Acquisition Of Promopharm

Jordanian drug maker Hikma Pharmaceuticals PLC acquired 63.9% of Moroccan branded generics firm Promopharm SA Oct. 3 in a cash deal worth $111.2 million. The acquisition gives Hikma access to the fourth largest pharmaceutical market in the Middle East and North Africa, additional manufacturing capacity and capability, and a perhaps stronger claim to its goal of being a partner of choice for multinationals across the MENA region

Hospira Hinges Emerging Market Success On Scale And Differentiation

Hospira Inc.'s new CEO Michael Ball laid out the company's strategic moves to expand in the fast-growing emerging markets during the company's Sept. 7 Investor's Day conference. The CEO said the U.S.-centric company's future growth hinges on expanding its footprint in emerging markets and launching more products including biosimilars in top pharmaceutical markets in Europe and Japan

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC073486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel